Tenecteplase Versus Alteplase for Stroke Thrombolysis Evaluation Trial in the Ambulance
Status:
Recruiting
Trial end date:
2022-03-30
Target enrollment:
Participant gender:
Summary
Ischemic stroke is a major health burden globally and in Australia. Treatment for ischemic
stroke is time critical and is significantly more effective if administered within the first
90 minutes of symptom onset. This clinical trial will identify if early administration of
oral thrombolytic agent, tenecteplase prior to hospital can improve outcomes from stroke, and
reduce costs compared to standard care of IV alteplase in hospital
Phase:
Phase 2
Details
Lead Sponsor:
Melbourne Health
Collaborator:
Austin Health, Eastern Health, Monash Health, Western Health, Alfred Health